Purespring Therapeutics is a gene therapy company that provides treatments for different kidney diseases.
Purespring Therapeutics has raised $104.5M in total funding. The most recent round was Series B. The last funding was announced in October 2024.
Purespring Therapeutics's investors include Sofinnova Partners, Forbion Capital Partners, Gilde Healthcare, British Patient Capital, Syncona Partners LLP.
Purespring Therapeutics is headquartered in London, United Kingdom.
Purespring Therapeutics is a gene therapy company that provides treatments for different kidney diseases.
Purespring Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Purespring Therapeutics — Funding & Investors." VCBacked, October 9, 2024, https://www.vcbacked.co/company/purespring-therapeutics. Accessed September 14, 2026.
VCBacked. (2024). Purespring Therapeutics — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/purespring-therapeutics
{{cite web |title=Purespring Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/purespring-therapeutics |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated